Modern Slavery Act Statement

Oxford Biomedica is opposed to slavery and human trafficking and believes that the Modern Slavery Act is a significant step in encouraging companies to identify and tackle the risks of modern slavery and human trafficking across the business operations and in supply chains.

This statement has been prepared in response to Section 54 of the Modern Slavery Act 2015 and outlines Oxford Biomedica's policies and efforts to mitigate the risks of modern slavery throughout our business and supply chain. This statement covers Oxford Biomedica's financial year from 01 January 2018 to 31 December 2018.

About our business and supply chain

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people.

Oxford Biomedica operates with responsibility at the forefront of our business. We are committed to sound corporate governance principles, practices and policies.

For further information about our business and governance policies, please visit: www.oxb.com

Our supply chain includes providers of client services and goods and services to our Group.

Managing modern slavery risks

Oxford Biomedica recognises our responsibility to identify, mitigate and address potential and actual human rights impacts that are directly linked to our business activities. While the risk of modern slavery and human trafficking is relatively lower in the highly regulated biopharmaceutical industry, we recognise that this responsibility also extends to our business relationships.

Oxford Biomedica has taken steps to mitigate the risks associated with modern slavery in our business and supply chain. These include the activities conducted in 2018:

- **Verification and risk assessment**: as part of the procurement solicitation process. All suppliers were asked to sign a statement in which they attest that their business meets specific human rights employment standards in accordance with the Modern Slavery Act. These standards include expectations that suppliers shall not use child labour or forced labour, and that they shall comply with legal minimum wage requirements, prevent discrimination or harassment in the workplace, and provide fair working conditions.

- **Vendor on-boarding**: once selected, all suppliers were asked to certify that products and their component parts that are provided to Oxford Biomedica comply with the laws regarding slavery and human trafficking of the country or countries in which they do business. The only exceptions are patient organisations, healthcare organisations and healthcare professionals which are not required to certify this given the nature of payments (typically honourarium, grants and sponsorships).

- **Employee training**: Oxford Biomedica's Code of Ethics outlines expectations for employees to conduct business with integrity. New employees were required to review the Code and complete the Code of Ethics training. The training includes a section on supplier conduct with a reference to our Responsible Supply Chain Management Policy, which includes human rights.
Improving in the year ahead

The progress Oxford Biomedica plans to make in 2018 includes:

- Including obligations in Oxford Biomedica’s new contracts that govern our extended supply chain
- Developing tools and processes to educate our people on how to engage with new and existing suppliers on this topic
- Conducting a risk assessment of existing suppliers to identify areas of highest risk within our supply chain

We will report on progress in our next statement.

This statement has been reviewed and endorsed by Oxford Biomedica’s Board of directors on 12 March 2019.

Signed

[Signature]

John Dawson
Chief Executive Officer